News | Stents Bioresorbable | October 15, 2015

SCAI: Bioabsorbable Stent Technologies Will Expand Options for Cardiovascular Disease Patients

Synergy and Absorb stents offer treatment for heart blockages without long-term complications of permanent stent components

SCAI, new bioabsorbable stent technologies, TCT 2015, Absorb, Synergy

Synergy stent image courtesy of Boston Scientific

October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients. 

One-year results from the ABSORB III trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2015 in San Francisco. The study met its primary endpoint, demonstrating the Absorb stent — which is fully absorbed by the body — performed as well as conventional stents at one year. Conducted at 193 sites, primarily in the United States, the ABSORB trial enrolled about 2,000 people with coronary artery disease.

The Society of Angiography and Cardiac Interventions (SCAI) issued a statement finding these initial data encouraging and that it looks forward to more long-term data over the next three to four years that will detail the benefits of this technology in participating patients. Although not yet commercially available in the United States, currently Absorb is available in more than 100 countries worldwide.

Last week, the U.S. Food and Drug Administration (FDA) approved Synergy, the first stent with a bioabsorbable polymer. Synergy’s drug coating and polymer are absorbed shortly after drug elution is complete at three months, leaving only the metal stent platform behind. This FDA approval is based on data from the EVOLVE II study, which showed Synergy performed as well as conventional stents at one year.

“These two new stents represent a new generation of stent technology. Both treat heart artery blockages like conventional stents, but are revolutionary in that they eliminate permanent stent components that occasionally cause long-term problems,” said SCAI Secretary Kirk Garratt, M.D., FSCAI. “These innovations highlight the interventional cardiology community’s continuous efforts to advance treatments that save lives and improve the quality of life for patients with cardiovascular disease.”

“Our goal is to ensure patients have the right treatment, at the right time,” said SCAI President James C. Blankenship, M.D., FSCAI. “Innovative technologies like bioabsorbable stents provide us with a wider array of options so we can offer patients the best possible treatment for their condition. We expect both stents will improve long-term outcomes for patients and reduce costs of treating coronary artery disease.”

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init